NantKwest Announces Achievement of End Point in Merkel Cell Carcinoma Phase II Trial With Evidence of Efficacy of Activated N...
15 11월 2016 - 6:08AM
Business Wire
Promising Clinically Meaningful Responses Seen Including a
Radiological Complete Response in Early Data Analysis Presented at
the 31st Annual Meeting of the Society for Immunotherapy of
Cancer
NantKwest Inc. (Nasdaq:NK), a pioneering, next generation,
clinical-stage immunotherapy company focused on harnessing the
unique power of the immune system using natural killer (NK) cells
to treat cancer, infectious diseases and inflammatory diseases,
announced a presentation of early analysis of the Company’s ongoing
Phase II Merkel cell carcinoma study at the 31st Annual Meeting of
the Society for Immunotherapy of Cancer (SITC) held November 9-13,
2016, in National Harbor, Maryland.
NantKwest’s presentation on Friday, November 11th, Adoptive
Cellular Therapy (ACT) With Allogeneic Activated Natural Killer
(aNK) Cells in Patients With Advanced Merkel Cell Carcinoma (MCC):
Preliminary Results of a Phase 2 Trial, highlighted interim results
from the Company’s ongoing Phase II clinical study of the Company’s
investigational aNK natural killer cell therapy in Merkel cell
carcinoma. Dr Shailender Bhatia from Fred Hutchinson Cancer
Research Center presented the first evidence of a radiological
complete response following single agent aNK infusion in a patient
with recurrent disease after multiple lines of therapy including
relapse after checkpoint inhibitor therapy.
Merkel cell carcinoma is a rare and aggressive skin cancer that
is increasing in incidence. Patients with metastatic or locally
advanced Merkel cell carcinoma have an extremely poor prognosis
with less than 20% of patients surviving longer than five
years.
Commenting on the results, Patrick Soon-Shiong, MD, Chairman and
CEO of NantKwest, said the following: “We are encouraged to see,
even in a heavily pretreated patient population, including patients
who have failed checkpoint inhibitor therapy, that our aNK natural
killer cell therapy exhibited clinically meaningful antitumor
activity, including a promising radiological complete response in
one patient, and we look forward to the rapid development of our
aNK program in Merkel cell carcinoma. In addition, through our
clinical development program, we strive to bring the potential for
long-term survival to a broad range of cancer patients in a number
of additional cancer indications.”
Dr. Soon-Shiong continued, “We believe this data, while a small
data set, provides the foundation to submit to the FDA our plans to
transition this trial to a pivotal study. Subject to FDA
authorization, this transitional study will include our aNK cell
therapy in combination with ALT-803, an investigational IL-15
superagonist complex shown to synergistically activate NK and T
cells in human clinical trials and currently in development by
Altor Biosciences. We believe this novel combination offers the
potential to further improve response rates and bring NantKwest’s
natural killer cell therapy one step closer to routine clinical
cancer care in a patient population in urgent need of better
treatment options.”
About NantKwest
NantKwest (Nasdaq:NK) is a pioneering, next generation,
clinical-stage immunotherapy company focused on harnessing the
unique power of our immune system using natural killer (NK) cells
to treat cancer, infectious diseases and inflammatory diseases. NK
cells are the body’s first line of defense due to the innate
ability of NK cells to rapidly identify and destroy cells under
stress, such as cancer or virally-infected cells.
NantKwest’s unique NK cell-based platform, with the capacity to
grow active killer cells as a biological cancer therapy, has been
designed to induce cell death against cancer or infected cells by
three different modes of action: (1) Direct killing using activated
NK cells (aNK) that release toxic granules directly into the cell
through cell to cell contact; (2) Antibody-mediated killing using
haNKs, which are NK cells engineered to incorporate a high affinity
receptor that binds to an administered antibody, enhancing the
cancer cell killing effect of that antibody; and (3) Targeted
activated killing using taNKs, which are NK cells engineered to
incorporate chimeric antigen receptors (CARs) to target
tumor-specific antigens found on the surface of cancer cells.
Our aNK, haNK and taNK platform addresses certain limitations of
T cell therapies including the reduction of risk of serious
“cytokine storms” reported after T cell therapy. As an
“off-the-shelf” therapy, NantKwest’s NK cells do not rely on a
patient’s own often compromised immune system. In Phase 1 clinical
trials in patients with late stage cancer, NantKwest’s NK cells
have been successfully administered as an outpatient infusion
therapy without any reported severe side effects, even at doses of
10 billion cells.
By leveraging an integrated and extensive genomics and
transcriptomics discovery and development engine, together with a
pipeline of multiple, clinical-stage, immuno-oncology programs that
include a Phase 2 trial for a rare form of melanoma and the planned
initiation of a clinical trial of NK cells targeted to breast
cancer, we believe NantKwest is uniquely positioned to be the
premier immunotherapy company and transform medicine by delivering
living drugs in a bag and bringing novel NK cell-based therapies to
routine clinical care. For more information, please visit
http://www.nantkwest.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161114006534/en/
NantKwest Inc.Jen Hodson, 562-397-3639jhodson@nantworks.com
NantKwest (NASDAQ:NK)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
NantKwest (NASDAQ:NK)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024